Tikehau Capital, the global alternative asset manager, and Goldman Sachs Asset Management announce today that they provided a HoldCo PIK facility to support Ardian’s acquisition of Biofarma, an Italian-based nutraceutical CDMO.
Through the provision of this facility, Tikehau Capital and Goldman Sachs Asset Management are partnering with Biofarma’s management team and Ardian to support the company’s growth strategy which seeks to consolidate the market in Europe.
With more than €230m revenue, Biofarma is a leading European CDMO player in the development, manufacturing and packaging of health supplements, medical devices, probiotic-based drugs, and cosmetics. The group is the result of a strong double-digit organic growth, coupled with a fruitful series of acquisitions implemented since 2017, combining Nutrilinea with five M&A targets in four years.
Luca Bucelli, Head of Italy at Tikehau Capital, said: “We are delighted to support again Ardian in another important transaction in Italy through a bespoke debt financing solution, and we look forward to working with the management team over the coming years. In addition to having a solid financial track record, Biofarma has a robust leading position in a growing market with significant entry barriers, proven resiliency, and strong underlying fundamentals. This transaction confirms the ability of our Private Debt platform to partner with best-in-class European companies”.